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Purpose 
 With current indications in breast, renal cell, brain, colorectal, and lung cancer, the anti-
VEGF antibody bevacizumab (Avastin©) is increasingly utilized to treat various advanced-stage 
malignancies, reflecting the growing understanding of VEGF-mediated angiogenesis for tumor 
survival and growth. However, as VEGF also mediates normal physiological processes 
including the vasodilation, increased vascular permeability, and angiogenesis crucial for proper 
wound-healing, bevacizumab use in the perioperative setting can also be expected to lead to 
both undesirable wound-healing complications (WHCs) and their potentially-serious sequelae. 
Current recommendations aim to minimize bevacizumab-related WHCs by employing a very 
conservative interval between bevacizumab cessation and surgical intervention, but these are 
based primarily on provider judgment and not clinical evidence. Therefore, this paper 
systematically reviews the current clinical evidence concerning the probability, nature, and 
timing of bevacizumab-related WHCs, in hopes to modify and/or refine current management 
recommendations. 
 
Introduction  
Vascular endothelial growth factor (VEGF) is a family of glycoproteins that activate 
receptor tyrosine kinases on endothelial cells and circulating endothelial progenitor cells. While 
VEGF has been shown to recruit and differentiate progenitor cells from bone marrow, enhance 
vascular permeability, promote monocyte chemotaxis, and regulate immune response, its key 
clinically-relevant role is stimulation of angiogenesis.[1] Angiogenesis, the proliferation of blood 
vessels from pre-existing vasculature, is crucial for tumor survival and growth.[2] VEGF has 
been shown to stabilize and enhance abnormal tumor vasculature[3], while normal human 
vasculature remains largely independent of VEGF for survival.[4] Such selectivity renders 
inhibition of VEGF-mediated angiogenesis a highly appealing strategy in cancer treatment.  
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 One such approach is bevacizumab (Avastin), an anti-VEGF monoclonal antibody that 
prevents downstream VEGF receptor activation in endothelial cells, causing anti-angiogenic 
inhibition of new tumor vasculature with normalization of existing tumor vasculature.[5, 6] These 
molecular effects have translated to improvements in clinical outcomes, as bevacizumab with 
chemotherapy improves response rates, progression-free survival, and overall survival in 
patients with various advanced-stage cancers over chemotherapy alone.[7] Currently, 
bevacizumab enjoys FDA indications for first or second-line treatment of metastatic colorectal 
cancer (mCRC) in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy, for 
first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous 
non-small cell lung cancer (NSCLC) in combination with paclitaxel and carboplatin 
chemotherapy, for second-line treatment of progressive disease glioblastoma multiforme (GBM) 
following prior single-agent therapy, and for metastatic renal cell carcinoma (RCC) in 
combination with interferon-alpha.[8]  
On the basis that “the modest benefit observed in breast cancer trials to-date with the 
substantial adverse reactions observed in breast cancer trials fails to provide a favorable risk-
benefit profile to support continued marketing of Avastin in a first-line metastatic breast cancer 
indication”[9], the FDA recently recommended withdrawing bevacizumab’s indication for 
metastatic HER2-negative breast cancer in combination with paclitaxel chemotherapy in 
patients who have not received prior chemotherapy. However, final decisions will be made 
pending a hearing with the manufacturer Genentech, so bevacizumab remains indicated for 
breast cancer at this time. Additional clinical trials are currently evaluating any therapeutic 
potential for treatment of endometrial, cervical, ovarian, gastric, prostate, and pancreatic 
cancers.[10-14] 
 The mammalian VEGF family consists of five glycoproteins: VEGFA, VEGFB, VEGFC, 
VEGFD, and PGF (placental growth factor). Of these, a specific 165-amino acid isoform of 
VEGFA is predominantly expressed in human solid cancers.[15] All bind to tyrosine kinase 
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receptors on target cells and initiate specific downstream signaling pathways.[16] VEGFR2, 
found exclusively on vasculature, mediates VEGF-induced angiogenesis. VEGFR1 is also found 
on vasculature and other cells but its function remains less elucidated. VEGFR3 preferentially 
binds VEGFC and VEGFD, is expressed on lymphatic endothelial cells, and mediates 
cardiovascular development and post-natal lymphangiogenesis.[15] 
 VEGF promotes tumor angiogenesis through several overlapping mechanisms: 
increased proliferation and survival of endothelial cells, increased migration and invasion of 
endothelial cells, increased permeability of pre-existing vasculature, and enhanced chemotaxis 
of bone marrow-derived endothelial progenitor cells.[15] Other non-vascular, pro-tumor VEGF 
effects include autocrine promotion of survival, migration, and invasion, suppression of host 
immune response, and aiding metastasis by targeting progenitor cells to destination organs.[17]  
Bevacizumab is a humanized monoclonal antibody with a circulating half-life of ~20 days that 
neutralizes the activity of VEGF by selectively binding VEGF-A and inhibiting downstream 
activation of the VEGF2R receptor on endothelial cells.[5] Inhibition of VEGF activity may block 
tumor growth through several parallel and/or overlapping mechanisms. In addition to simply 
stopping further outgrowth of pre-existing vessels (so-called classical “sprouting angiogenesis”), 
VEGF inhibition may also vasoconstrict and normalize existing tumor vasculature, induce 
endothelial-cell apoptosis, sensitize tumor cells to concurrent chemotherapy, prevent 
recruitment of hematopoietic and endothelial progenitor cells, and directly impair tumor cell 
growth and metastasis.[15]  
However, as VEGF also mediates many normal physiological processes, VEGF-targeted 
therapy can lead to multiple adverse reactions. For example, VEGF inhibition leads to 
decreased nitric oxide (NO) production in arteriolar walls resulting in vasoconstriction and 
consequently increased blood pressure[18], while proteinuria results from inhibition of VEGF-
dependent interactions between podocytes and glomerular endothelial cells that disrupt the 
normal filtration barrier.[19] Although generally well-tolerated, bevacizumab therapy carries a 
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specific adverse reaction profile relating to inhibition of VEGF-mediated physiological 
processes. These toxicities include hypertension, proteinuria, gastrointestinal perforation, 
hemorrhage and other bleeding events, arterial thromboembolism, cardiac toxicity, 
leukoencephalopathy, rash, infusion-related hypersensitivity reactions, congestive heart failure, 
and hypothyroidism.[20-22] Literature regarding the pathophysiology, preclinical and clinical 
evidence, and optimal management recommendations for other bevacizumab-associated 
toxicities has been well-characterized elsewhere.[20-24]  
Notably, angiogenesis is also crucial for proper wound repair[25], so bevacizumab also 
poses an increased risk of impaired wound healing[20], an important consideration in the 
perioperative care of patients receiving such therapy. Proper wound healing requires a highly 
structured and sequential series of events including phagocytosis, coagulation, chemotaxis, 
mitogenesis, and synthesis of collagen and other matrix components, and involves recruitment 
of various cell lineages including platelets, neutrophils, macrophages, lymphocytes, and 
fibroblasts, in that order.[26]  
VEGF plays a role in many of these steps. First, after tissue injury, activated platelets 
release VEGF which helps recruit macrophages, fibroblasts, and endothelial cells. Second, 
monocytes also release VEGF which stimulates other monocytes to migrate into and remodel 
clots. Third, VEGF increases microvascular permeability which enhances both the early 
inflammatory response where recruited granulocytes clear bacteria and other wound debris and 
the late inflammatory response where recruited macrophages phagocytose debris and produce 
growth factors necessary for extracellular matrix production. Fourth, fibroblasts that deposit 
types I and III collagen to form new extracellular matrix also release VEGF.[26] Increased VEGF 
expression correlates with wound hypoxia and occurs as early as 3 days after wound induction 
before returning to normal levels by 3 weeks.[27] 
Ultimately, VEGF mediates three effects for wound healing: vasodilation, increased 
vascular permeability, and angiogenesis. Potent vasodilation increases blood flow up to fivefold 
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and significantly aids oxygen and glucose delivery and waste removal.[26] Increased vascular 
permeability permits extravasation of fibrinogen, plasminogen, and other plasma proteins to 
help produce a pro-angiogenic extracellular matrix rich in fibrin and fibronectin, a substrate for 
further tissue regrowth.[26, 28] Angiogenesis occurs throughout these phases and remains 
crucial for proper wound healing.[25]  
The above pathophysiological evidence suggests that bevacizumab therapy may 
increase the risk of undesirable wound-healing complications (WHCs). In fact, many of the 
clinical trials conducted to test the efficacy and effectiveness of bevacizumab in its various 
oncological indications have specifically reported wound-healing complications as part of 
bevacizumab’s toxicity profile. However, there remains no high-quality systematic review 
concerning the probability, timing, and nature of wound-healing complications resulting from 
bevacizumab use. 
 As bevacizumab therapy expands in clinical use in the oncological setting, and as many 
cancer patients undergo post-oncological aesthetic reconstruction, knowledge of its specific 
toxicity profile will become increasingly important, especially for the plastic surgeon who will 
increasingly be entrusted with proper wound care and elective reconstructions in these patients. 
As such, knowledge of the incidence, timing, and nature of bevacizumab-induced WHCs is 
increasingly critical to guide therapy and outline optimal evidence-based management 
recommendations. Therefore, this paper will systematically review the current clinical evidence 
to estimate the risk, timing, and nature of WHCs in patients who receive perioperative 
(neoadjuvant or adjuvant) bevacizumab. 
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Methods 
 The purpose of this paper is to systematically review the current clinical evidence to 
assess the probability, timing, and nature of wound-healing complications while receiving 
bevacizumab therapy in the oncological setting. Literature regarding the pathophysiology, 
preclinical and clinical evidence, and optimal management recommendations for other 
bevacizumab-associated toxicities has been well-characterized elsewhere[20-24]. The final 
work plans for this review were developed by the authors. 
 
Data Sources and Searches 
 To identify relevant studies, we conducted a MEDLINE (1980 to June 11, 2011) search 
using the MESH headings “bevacizumab”, “avastin”, “mechanism”, “complication”, “wound”, 
“surgery”, “colorectal”, “breast”, “renal cell”, “brain”, “lung”, and “cancer.” Each search was 
limited to studies and trials performed in humans, as preclinical and pathophysiological 
evidence was excluded. Furthermore, studies were limited to those published in the English 
language. We also hand searched the bibliographies of included articles, searched our own 
files, and queried content experts at our institution to identify additional possibly-relevant studies 
as well. In addition, we also performed related articles searches of all included MEDLINE 
articles. 
  
Study Selection 
 We included studies of any design that were conducted in academic institutions and 
have been necessarily approved by the Institutional Review Board (IRB). Studies had to specify 
an intervention of FDA-approved bevacizumab therapy given to a patient with an oncological 
diagnosis. Neoadjuvant bevacizumab had to be given at most 60 days (~8 weeks) before 
surgical intervention, while adjuvant bevacizumab had to be given at most 60 days (~8 weeks) 
after. Studies had to specifically report a wound-healing complication rate that specified the 
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nature and timing of WHCs, although this did not have to be the study’s primary outcome of 
interest. Furthermore, studies had to report a follow-up period of at least one year, with wound-
healing complications occurring one year after cessation of bevacizumab therapy not 
considered a bevacizumab-related WHC. The primary outcome of interest for this study was the 
incidence of WHC, with timing and nature being secondary outcomes of interest. 
  
Table 1. PICOTTS Eligibility Criteria for Studies Included In Review. 
 Inclusion Exclusion 
Population Patients with oncological 
diagnoses receiving bevacizumab 
for an FDA-approved indication 
Patients with oncological diagnoses 
receiving bevacizumab as off-label 
use not currently approved by the 
FDA, or patients without oncological 
diagnoses 
Intervention Bevacizumab therapy occurring 
around or during surgical 
intervention, with or without 
concurrent chemotherapy 
Bevacizumab therapy with or 
without concurrent chemotherapy 
occurring without any reported 
surgical intervention 
Control Chemotherapy with surgical 
intervention, but control group not 
necessary 
Chemotherapy without surgical 
intervention 
Outcome Clinical outcome where the 
incidence, timing, and nature of 
predefined wound-healing 
complications specifically 
reported; did not have to be 
primary outcome of study 
Wound-healing complications not 
specifically defined, timing and 
nature not provided, any 
intermediate outcomes 
Time (intervention) Neoadjuvant bevacizumab given 
at most 60 days (~8 weeks) before 
surgery and/or adjuvant 
bevacizumab given at most 60 
days (~8 weeks) after surgery 
Neoadjuvant bevacizumab given 
more than 60 days (~8 weeks) 
before surgery and/or adjuvant 
bevacizumab given more than 60 
days (~8 weeks) after surgery 
Time (follow-up) Patient follow-up of at least one 
year after cessation of 
bevacizumab therapy, with any 
reported WHCs occurring one 
year after bevacizumab cessation 
discounted 
Patient follow-up less than one year 
after cessation of bevacizumab 
therapy 
Study Design Randomized-controlled trials, 
cohort studies, case control, or 
case series of at least 40 patients 
Single case report, any study with 
less than 40 patients 
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We excluded studies that did not clearly define what was considered a wound-healing 
complication, contained less than 40 patients, received neoadjuvant bevacizumab more than 60 
days before surgery and/or adjuvant bevacizumab more than 28 days after surgery, did not 
report the timing of wound-healing complications, did not have a quantitative study design, did 
not include some type of surgical intervention, applied bevacizumab therapy as off-label use 
and/or in patients without oncological diagnoses, did not have at least a one-year median follow-
up period, or were perceived to be very poor quality upon initial examination. 
 
Study Type 
 The following study types were considered acceptable for inclusion: case series, case-
control analyses, cohort studies, randomized-controlled trials. The following study types were 
not considered acceptable and excluded: single case report, expert opinion. 
 
Data Extraction  
 Both authors independently reviewed titles, abstracts, and full articles (if necessary) to 
determine inclusion eligibility, with disagreements resolved by discussion. The first author 
abstracted study information into tables, with both checking information for accuracy. Both 
authors independently assessed study quality and then compared results, with disagreements 
resolved by discussion as well. 
 
Quality Assessment 
 Quality was graded using criteria adapted from the United States Preventive Services 
Task Force (USPSTF) which had been used in numerous previous reviews. For each study, 
reviewers graded pre-specified criterion as good (G), fair (F), or poor (P). Ratings for each time 
were converted into numerical values as follows: good = 2, fair = 1, and poor = 0. Then, a 
composite score consisting of the average of these ratings was calculated and reported for each 
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study, with each item weighted equally. The final quality of the study was determined by the 
composite score, with 1.5 or higher considered good (G), 1.0 to 1.49 considered fair (F), and 
less than 1.0 considered poor (P). 
 
Measurement Assessment 
 To be included in this review, studies had to specifically define what criteria was used to 
define all wound-healing complications. Such criteria had to be constructed before 
implementation of the study, had to be consistently applied to all study patients, and had to 
consist of clinically-documented events determined to be WHCs by providers. WHC criteria did 
not necessarily have to include severity of each complication. The bevacizumab dose had to be 
specifically reported and had to be consistent with FDA-approved dosing by indication. 
 
Data Synthesis and Analysis 
 After data abstraction and quality assessment, this study’s authors met for discussion 
about result, comparing and contrasting relevant features of studies, prioritizing certain study 
sizes and designs, and continuing iterative review until reaching consensus about key message 
and conclusions. No meta-analyses could be performed to the heterogeneity of study 
populations, oncological diagnoses, timing and duration of bevacizumab therapy, and wound-
healing complication definitions. 
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Results 
Search Results 
Overall, we identified eight articles that were reviewed in final analysis and included in 
our review; all eight were identified through primary literature search and none through hand 
review or expert inquiry (Figure 1). 
 
Figure 1. Flowchart for Study Inclusion Process. 
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Study Design 
 A summary of included studies is provided in Table 2. One (Allegra et al. [29]) was a 
high-powered prospective randomized controlled trial. Two (Kozloff et al. [30], Jonasch et al. 
[31]) were prospective cohort analyses, one (Gruenberger et al. [32]) was a prospective case 
series, one (Scappaticci et al. [33]) was a retrospective case-control study, and another three 
(Kesmodel et al. [34], Clark et al. [35], Golshan et al. [36]) were retrospective case series.  
 
Table 2. Summary of Included Articles.  
Source Indication
1
 Design Quality 
Grade
2
 
Sample 
Size 
Therapy 
Timing 
Interval WHC Definition WHC 
rate 
Gruenberger, 
et al. 2008 
mCRC Case 
series 
1.2 (F) 56 Neoadjuvant 
+ adjuvant 
35 d, 
35 d 
CTCAEv3
3
 0% 
Kesmodel, et 
al. 2008 
mCRC Case 
control 
1.4 (F) 81 Neoadjuvant 49 d Infection or 
collection that 
required partial 
wound opening and 
local wound care, 
wound complication 
requiring surgery, 
other 
28% 
Kozloff, et al. 
2009 
mCRC Cohort 1.4 (F) 521 Neoadjuvant ≤ 60 d Wound dehiscence, 
wound infection, 
wound bleeding, 
other wound 
complications 
4.4% 
Scappaticci, 
et al. 2005 
mCRC Case 
control 
1.8 (G) 75 
 
Neoadjuvant 
Adjuvant 
 
≤ 60 d 
28-60 d 
Abnormal or delayed 
healing, wound 
dehiscence, bowel 
perforation, fistula, 
abscess, 
hemorrhage 
13% 
1.3% 
Allegra et al. 
2009  
mCRC RCT 1.8 (G) 1,326 Adjuvant 46 d CTCAEv3
3
 1.7% 
Clark et al., 
2010 
GBM Case 
series 
0.6 (P) 41 Neoadjuvant 
+ adjuvant 
36 d Infection, 
dehiscence, CSF 
leakage, 
pseudomeningocele, 
osteomyelitis 
22% 
Golshan et 
al., 2011 
Breast Case 
series 
0.8 (P) 51 Neoadjuvant 
+ adjuvant 
42 d, 
21 d 
Seroma, abscess, 
hematoma, native 
flap necrosis, 
reconstruction flap 
necrosis, cellulitis 
requiring antibiotics 
43% 
Jonasch et 
al., 2009 
RCC Cohort 1.0 (F) 50 Neoadjuvant 28 d Wound dehiscence, 
delayed wound 
healing 
24% 
1 
Indication: mCRC = metastatic colorectal cancer, GBM = glioblastoma multiforme, RCC = renal cell carcinoma 
2 
As described in the “Data Extraction and Quality Assessment” subsection of “Methods”, each study’s quality was 
graded according to a composite score that ranked each component as good (G), fair (F), or poor (P) 
3 
National Cancer Institute’s 2003 Common Terminology Criteria for Adverse Events version 3.0[37] 
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Study and Source Populations and Measurement Outcomes 
Included studies spanned four of bevacizumab’s five current oncological indications: 
metastatic colorectal cancer (Gruenberger et al., Kozloff et al., Kesmodel et al., Scappaticci et 
al., Allegra et al.), glioblastoma multiforme (Clark et al.), renal cell carcinoma (Jonasch et al.), 
and breast cancer (Golshan et al.). Notably, no studies met the inclusion and exclusion criteria 
for the remaining indication of non-small cell lung cancer. In addition, the timing of bevacizumab 
therapy ranged from exclusively neoadjuvant (Kozloff et al., Kesmodel et al., Scappaticci et al., 
Jonasch et al.) to exclusively adjuvant (Allegra et al.) to combined neoadjuvant and adjuvant 
regimens (Gruenberger et al., Clark et al., Golshan et al.). The duration of the bevacizumab-
surgery interval ranged from 28-60 days in the neoadjuvant setting to 21-36 days in the adjuvant 
setting. 
Three included studies (Gruenberger et al., Allegra et al., Jonasch et al.) were trials 
evaluating the efficacy of novel bevacizumab-containing chemotherapy regimens and therefore 
had primary efficacy outcomes of all-cause mortality or progression-free survival, though 
specific wound-healing complications were reported as part of an overall safety and toxicity 
profile. The remaining five studies (Kesmodel et al., Kozloff et al., Scappaticci et al., Clark et al., 
Golshan et al.) were constructed to specifically examine the incidence of bevacizumab-related 
wound-healing complications and thus had primary safety outcomes of postoperative wound-
healing complication incidence.   
 
Critical Appraisal of Included Studies 
 Tables 3a and 3b provide a summary of critical appraisal of the eight included studies; 
justification for overall study quality rating can be found here. 
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Table 3a. Critical Appraisal of Included Studies. 
 Gruenberger et al. Kesmodel et al.  Kozloff et al.  Allegra et al. 
Design Prospective, single-center, 
nonrandomized phase II 
clinical trial (case series) 
evaluating efficacy and 
toxicity of bevacizumab 
with capecitabine and 
oxaliplatin as neoadjuvant 
therapy for metastatic 
colorectal cancer 
Retrospective case-
control analysis 
evaluating 
postoperative 
complication rate 
after neoadjuvant 
bevacizumab vs. 
chemotherapy and 
mCRC hepatectomy 
Prospective, multi-
center cohort study 
to elucidate safety 
and effectiveness of 
bevacizumab-
containing 
chemotherapy for 
mCRC 
Prospective, phase 
III RCT to evaluate 
the safety and 
effectiveness of 
adjuvant 
bevacizumab with 
FOLFOX 
chemotherapy for 
stage II and III CRC. 
Source 
population 
Patients from Europe and 
United States with 
surgically resectable stage 
IV colorectal cancer 
metastasized to liver 
Patients from the 
United States with 
isolated hepatic 
metastases from 
colorectal cancer 
United States 
patients with 
previously untreated 
mCRC 
United States 
patients with stage II 
and III colorectal 
cancer 
Study 
population 
56 patients with 
histologically-confirmed 
resectable mCRC hepatic 
metastases at high risk for 
early recurrence, with 
ECOG performance status 
0-1 and adequate bone 
marrow reserve and renal 
and hepatic function. 
Exclusion criteria: prior 
chemotherapy, prior 
coagulopathy, CNS 
metastases, significant CV 
disease 
125 patients who 
received neoadjuvant 
chemotherapy (44 
chemo only, 81 with 
bevacizumab) at a 
median of 58 days 
prior to hepatic 
mCRC resection. 
Study did not report 
specific exclusion 
criteria, other than 
assumed surgical 
resectability 
1,953 patients with 
locally advanced or 
metastatic CRC 
previously untreated 
receiving a 
bevacizumab-
containing 
chemotherapy 
regimen, of which 
521 subsequently 
underwent surgical 
resection within 60 
days. No exclusion 
criteria specified 
2,710 patients with 
stage II or III CRC 
randomized to 
receive adjuvant 
FOLFOX (1,356) or 
adjuvant FOLFOX + 
bevacizumab (1,354) 
after undergoing 
surgical resection. 
Exclusion criteria: 
history of stroke, 
TIA, vascular 
disease, arterial 
thrombosis (MI). 
Initial 
comparability 
of groups 
Not applicable, as no 
control group 
Comparable, as did 
not differ by age, 
stage, comorbidity, 
BMI, tumor size, or 
procedural variables. 
Bevacizumab group 
did have more 
metastatic liver 
lesions (p = 0.04). 
Not applicable, as no 
control group 
Comparable, as did 
not differ by age, 
gender, stage, and 
race. Study did not 
report patient 
comorbidity and 
procedural variables, 
but randomized so 
should be similar too 
Drop-outs, 
adherence, 
cross-overs 
Study did not report any 
drop-outs or adherence 
issues; cross-overs not 
applicable 
Study did not report 
drop-outs, cross-
overs, or adherence 
issues 
Of the initial 1,953, 
83 (4%) dropped out, 
150 (8%) were lost 
to follow-up, and 88 
(4%) withdrew 
Of the 1,354 
assigned to 
bevacizumab, 22 
(1.6%) dropped out. 
No cross-overs 
Selection 
bias
¶
 
Intermediate potential (fair), 
as only 56 subjects were 
enrolled and assessed as 
“surgically resectable” and 
“high risk of recurrence” 
according to clinical 
judgment 
Intermediate 
potential (fair), as 
subjects were initially 
enrolled into groups 
according before 
study by varying 
criteria over time 
Low potential (good). 
To reduce selection 
bias, sites were 
instructed to recruit 
all eligible patients, 
but no non-enrolled 
patient log was kept 
Low potential (good), 
as both arms were 
randomized after 
stratifying by number 
of positive lymph 
nodes 
Outcome 
measurement 
WHCs graded via 
CTCAEv3.0 
Wound infection or 
collection requiring 
surgery, other 
Wound dehiscence, 
infection, bleeding, 
and other wound 
complications 
WHCs graded via 
CTCAEv3.0 
Measurement 
bias
¶
 
Low potential (good), as 
CTCAEv3.0 provides a 
systematic and consistent 
independent guideline to 
evaluate specific toxicities 
in oncological patients, thus 
Intermediate 
potential (fair), as 
WHCs not clearly or 
systematically 
defined by 
independent system, 
Low potential (good). 
Though WHCs not 
independently set, 
high sample size 
would neutralize 
random biases from 
Low potential (good), 
as CTCAEv3.0 
provides a 
systematic, 
independent 
guideline to evaluate  
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equal, valid, and reliable and can vary heavily 
by clinician 
clinical judgment, 
and centers agreed 
on same WHCs 
toxicities, thus equal, 
valid, and reliable 
Confounders Age, tumor stage, patient 
comorbidity that could 
independently affect 
wound-healing (obesity, 
diabetes, nutrition status) 
Age, tumor stage, 
comorbidity 
(diabetes, CV 
disease), BMI, 
procedural variables 
(duration, EBL, type) 
Age, tumor stage, 
tumor size and site, 
comorbidity 
(diabetes, PAD, 
BMI), procedural 
variables 
Age, stage, tumor 
size and site, 
comorbidity (BMI, 
diabetes, nutrition 
status), procedural 
variables 
Confounding 
potential
¶
 
High potential (poor), as 
study was single-arm of 56 
patients and patient 
comorbid conditions were 
not reported or controlled 
Low potential (good), 
as two groups were 
similar and most 
known confounders 
reported and 
controlled for 
Low potential (good), 
as most known 
confounders were 
reported and 
controlled for in 
multivariate analysis 
Low potential (good), 
as study was large 
and randomized, so 
confounders 
controlled for even if 
not reported 
Analysis Efficacy (tumor response) 
and safety (rate of grade 
3/4 adverse events) 
Incidence of post-
operative wound-
healing complication 
WHC incidence in 
subgroup of patients 
undergoing surgery 
Effectiveness (PFS) 
and safety (rate of 
grade 3/4 toxicities) 
Results 0% rate of grade ¾ wound-
healing complications 
25% chemo vs. 28% 
bevacizumab, p = 
0.68 
23/521 (4.4%, 95% 
CI 2.7-6.2%) WHC 
rate 
1.7% bevacizumab 
vs. 0.3% FOLFOX 
only, p < 0.01 
Clinical 
importance 
Significant, as 
bevacizumab expands in 
use as perioperative 
therapy for oncological 
patients who undergo 
surgical resection 
Significant, as 
bevacizumab is 
increasingly used as 
neoadjuvant therapy 
for hepatic mCRC 
Significant, as 
bevacizumab is 
increasingly used as 
neoadjuvant therapy 
for hepatic mCRC 
Significant, as 
bevacizumab is 
increasingly used in 
adjuvant setting for 
CRC, even if not 
metastatic 
Internal 
validity
¶
 
Good. Strict inclusion and 
exclusion criteria. 
Fair. Moderate 
inclusion criteria, no 
exclusion criteria 
Fair. Inclusion 
criteria specified 
first-time treatment 
Good. Strict 
inclusion and 
exclusion criteria. 
External 
validity
¶
 
Fair. Strict inclusion and 
exclusion criteria 
decreased external validity, 
as mCRC patients who are 
not surgically resectable or 
considered to be “high risk 
of recurrence” were 
excluded, and results are 
less applicable to broader 
source population 
Good. Inclusion 
criteria broadly-
defined and no 
exclusion criteria, so 
results more 
applicable to broader 
source population of 
mCRC patients with 
hepatic metastases 
Good. Broad 
inclusion criteria 
roughly applicable to 
source population of 
mCRC patients not 
previously treated, 
with no exclusion 
criteria 
Fair. Applicable only 
to stage II and III 
colorectal cancer 
patients and not 
stage IV metastatic, 
which is the 
population in which 
bevacizumab is most 
applied in the 
oncological setting 
Comments Although limited sample 
size and high potential for 
confounding, study did 
indicate that neoadjuvant 
bevacizumab for hepatic 
metastectomy can be well-
tolerated, indicating need 
for further research 
Although 
retrospective, study 
best controlled for 
known confounders 
and did not find 
increased post-
operative WHC risk 
in bevacizumab-
containing regimen, 
though may be 
underpowered due to 
overall small n 
Prospective, high 
powered (large 
sample size), and 
controlled for known 
patient confounders 
though not for 
procedural variables 
(type, duration, 
tumor resectability, 
etc…) 
Prospective, high 
powered (large 
sample size), and 
randomized, these 
results reinforce a 
higher WHC risk 
from adjuvant 
bevacizumab, but 
only apply to stage II 
and III CRC patients, 
which have easier 
resections than IV 
¶ Graded as good (2), fair (1), or poor (0), with a composite average then recorded as study’s overall quality 
 
 
 
 
 
 
 
 
 
16 
 
Table 3b. Critical Appraisal of Included Studies (continued). 
 Scappaticci et al. Clark et al. Golshan et al. Jonasch et al. 
Design Retrospective, case-control 
analysis to assess 
postoperative WHC rate 
after neoadjuvant 
bevacizumab from two 
randomized studies in 
mCRC patients 
Retrospective single-
center case-series to 
assess wound 
healing complication 
risk of second or 
third craniotomies for 
recurrent GBM 
Prospective single-
center trial to assess 
surgical morbidity of  
neoadjuvant 
bevacizumab for 
triple-negative breast 
cancer 
Prospective non-
comparative phase II 
(cohort) trial 
evaluating efficacy 
and safety of 
neoadjuvant 
bevacizumab in RCC 
Source 
population 
United States patients with 
previously untreated mCRC 
considered surgically 
resectable 
United States 
patients with 
surgically-resectable 
recurrent GBM 
United States 
patients with triple-
negative resectable 
breast cancer 
United States 
patients with 
surgically-resectable 
RCC 
Study 
population 
1,132 previously-untreated 
mCRC patients: 516 got 
chemotherapy alone, 616 
bevacizumab of which 305 
received resection (230 
neoadjuvant, 75 adjuvant). 
Exclusion criteria: major 
surgery up to 28 days 
before, vascular disease 
and/or coagulopathy 
209 patients who 
underwent repeat 
craniotomy for 
recurrent GBM and 
had received 
adjuvant chemo-
radiation after first 
resection. Exclusion: 
patients with 
implantable agents, 
emergent surgeries, 
prior scalp infection 
51 patients with 
triple-negative breast 
cancer who got 
neoadjuvant 
bevacizumab before  
lumpectomy (n = 29) 
or mastectomy (n = 
22) versus 28 
patients who got 
neoadjuvant cisplatin 
alone. No exclusion 
criteria specified. 
52 patients with 
resectable RCC got 
neoadjuvant 
bevacizumab before 
cytoreductive 
nephrectomy 4 
weeks later. 
Inclusion: adequate 
bone marrow and 
liver function. 
Exclusion: brain 
metastases, prior 
systemic therapy 
Initial 
comparability 
of groups 
Comparable, as the two 
groups (chemotherapy 
alone, chemotherapy + 
bevacizumab) were pooled 
from two other randomized 
studies 
Not applicable, as no 
control group 
Groups did not differ 
by age, mean tumor 
size, or resection 
type (BCT vs. 
mastectomy), but 
differed by stage 
Not applicable, as 
single-arm and no 
control group 
Drop-outs, 
adherence, 
cross-overs 
Study did not report drop-
outs, cross-overs, or 
adherence issues 
N/a. Retrospective, 
so no dropouts after 
initial exclusion 
No dropouts, cross-
overs, or adherence 
issues reported 
Of 52, 2 (4%) 
dropped out and 8 
(16%) lost to f/u 
Selection 
bias
¶
 
Low potential (good), as 
study pooled data from two 
other randomized studies 
using computers, which 
minimizes selection bias. 
High potential (poor), 
as no consistent 
criteria defined or 
reported for why 
study patients got 
bevacizumab in 
addition to standard 
chemoradiation 
before or after 
recurrent GBM 
resection 
Intermediate 
potential (fair). Both 
arms had similar 
inclusion criteria that 
was clearly 
specified, though 
selection into 
bevacizumab arm or 
not was offered by 
clinician without 
oversight 
Intermediate 
potential (fair). 
Prespecified and 
clear inclusion 
criteria, but whether 
or not bevacizumab 
was offered 
depended on clinical 
judgment 
Outcome 
measurement 
WHCs graded via 
CTCAEv3.0 
Surgical site 
infection, wound 
dehiscence, CSF 
leakage, pseudo-
meningocele, bone 
flap osteomyelitis 
Seroma, abscess, 
hematoma, native 
flap necrosis, 
reconstruction flap 
necrosis, cellulitis 
requiring antibiotics 
Wound dehiscence, 
delayed wound 
healing 
Measurement 
bias
¶
 
Low potential (good), as 
CTCAEv3.0 provides a 
consistent, systematic and 
independent guideline, thus 
equal, valid, and reliable 
Low potential (good), 
as single reviewer 
used same 
specifically-defined 
WHC criteria for all 
cases, thus equal, 
valid, and reliable 
Intermediate 
potential (fair), as 
authors did use 
prespecified criteria, 
but criteria were 
broad, vague, and 
not graded 
High potential (poor). 
WHC criteria were 
vague, especially 
“delayed wound 
healing”, so not very 
equal, valid, and/or 
reliable 
Confounders Age, tumor stage, tumor 
size and site, comorbidity 
Age, tumor stage, 
tumor size and 
Age, tumor stage, 
tumor location, 
Age, tumor stage, 
tumor location and 
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(BMI, diabetes, CV 
disease), procedural 
variables  
location, patient 
comorbidity (BMI, 
diabetes, nutrition 
status, CV disease), 
prior treatment 
(chemoradiation), 
procedural variables 
patient comorbidity 
(BMI, diabetes, 
nutrition status, CV 
disease), prior 
radiation therapy, 
procedural variables 
size, patient 
comorbidity (BMI, 
diabetes, nutrition 
status, CV disease), 
prior radiation 
therapy, procedural 
data (length, etc…) 
Confounding 
potential
¶
 
Low potential (good), as 
data was pooled from two 
other randomized studies 
which minimizes 
confounding. 
High potential (poor), 
as possible 
confounders not 
reported or 
controlled for in 
analysis 
High potential (poor). 
Small study with no 
methodology that 
reported and 
controlled for many 
likely confounders 
High potential (poor). 
Study did not report 
or control for most 
likely confounders in 
analysis, simply 
reporting crude rate 
Analysis Postoperative WHC 
incidence 
Postoperative WHC 
incidence 
Postoperative WHC 
incidence 
Postoperative WHC 
incidence 
Results 3/230 (1.3%, 95% CI 0.3-
3.8%) adjuvant; 10/75 
(13%, 95% CI 7-23%) 
neoadjuvant 
Overall 9/41 (21.9%) 
Neoadjuvant 8/23 
34.8%), adjuvant 
1/18 (5.6%) 
11/28 (39%) cisplatin 
vs. 22/41 (43%) in 
bevacizumab, p = 
0.82 
12/50 (24%) WHC 
rate after 
neoadjuvant 
bevacizumab 
Clinical 
importance 
Significant, as bevacizumab 
is used as adjuvant and 
neoadjuvant therapy for 
hepatic mCRC 
Significant, as 
bevacizumab is 
indicated for 
recurrent GBM now 
Significant, as 
bevacizumab is used 
for neoadjuvant 
therapy, and many 
breast cancer 
patients undergo 
immediate 
reconstruction 
Significant, as 
bevacizumab is 
increasingly used 
before cytoreductive 
nephrectomy for 
RCC 
Internal 
validity
¶
 
Good. Strict inclusion and 
exclusion criteria 
Fair. Results 
applicable to study 
population 
Fair. Inclusion 
criteria defined, no 
exclusion criteria 
Good. Strict 
inclusion and 
exclusion criteria. 
External 
validity
¶
 
Fair. Strict inclusion and 
exclusion criteria from 
randomized studies but no 
selection bias means study 
population approximates 
source population fairly 
Poor. Study did not 
specify inclusion or 
exclusion criteria or 
indicate why patients 
got bevacizumab for 
recurrent GBM over 
just chemoradiation, 
so less applicable to 
overall source 
population of 
recurrent GBM 
patients 
Fair. Clear inclusion 
criteria but no 
exclusion criteria, 
though should apply 
to source population 
of triple-negative 
breast cancer 
Good. Study 
population 
approximates source 
population well, as 
exclusion criteria did 
not leave out most 
patients in the U.S. 
with RCC 
Comments Although retrospective, this 
study pooled data from two 
randomized and high-
powered studies, with little 
measurement bias, and 
thus well evaluates WHC 
incidence in the 
neoadjuvant and adjuvant 
setting 
Retrospective and 
small study which 
didn’t report and 
control for numerous 
confounders, high 
selection bias 
potential, and limited 
external validity, 
these findings are 
uncertain 
Although prospective 
and comparative, 
this study was small 
with no method to 
control for many 
possible 
confounders and/or 
other biases, and as 
such results are very 
uncertain 
Retrospective and 
small, this study 
didn’t control for 
most variables that 
could confound 
impaired wound-
healing, making 
results very 
uncertain 
¶ Graded as good, fair, or poor, with a composite average then recorded as study’s overall quality 
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Measurement Bias Potential 
All studies explicitly defined what they considered a wound-healing complication, but this 
definition was not necessarily consistent from one study to the next, as evidenced in Table 2. 
Inconsistency and inherent subjectivity in WHC definition rendered each of the studies to be at 
risk for measurement bias. 
Several considerations were consistent across all studies and could have led to possible 
measurement bias. First, none of the eight studies included any type of blinding when 
measurements were being recorded, as providers were always aware of which patients were on 
bevacizumab therapy. This introduces some potential measurement bias in all eight studies.  
However, blinding may not be feasible, as wound-healing complications are recorded by the 
same surgical oncologists who provide appropriate follow-up after surgical intervention, and 
therefore must be aware if the patient received neoadjuvant or adjuvant bevacizumab. 
Nonetheless, this consideration should be taken into account when assessing measurement 
bias. 
Second, the dose of bevacizumab did vary between studies but was consistent with 
FDA-approved dosing. For GBM, Clark et al. used 10 mg/kg. For breast cancer, Golshan et al. 
used 15 mg/kg. For mCRC, Gruenberger et al., Kozloff et al., Kesmodel et al., Allegra et al., and 
Scappaticci et al. all used 5 mg/kg. Finally, for RCC, Jonasch et al. provided 10 mg/kg. The 
variations in dosing introduce possible measurement bias as higher bevacizumab doses may 
lead to higher reported WHCs. 
Five of the eight studies had little potential for measurement bias. Gruenberger et al., 
Scappaticci et al., and Allegra et al. utilized the increasingly-favored CTCAEv3.0[37], which 
provides systematic, consistent, and independently-determined guidelines to evaluate and 
grade adverse reactions in oncological settings, including wound-healing. This makes 
measuring WHCs equal, valid, and reliable, and thereby minimizes measurement bias. On the 
other hand, Clark et al.’s differing WHC criteria included CSF leakage, pseudomeningocele 
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formation, and osteomyelitis, as the location of the craniotomy incision in the scalp for GBM 
warrants these specific considerations as possible sequelae secondary to impaired wound-
healing. Since a single author reviewed all cases retrospectively in this study with a 
predetermined and specific set of criteria, measurement bias potential was minimized here too. 
Finally, although Kozloff et al. used a broader WHC definition that included dehiscence, 
infection, bleeding, and “other”, the large sample size (n = 521) means random biases from 
clinical judgment are more likely to be neutralized. 
Two of the eight studies had intermediate potential for measurement bias. Kesmodel et 
al. defined WHCs as any “infection or collection requiring wound opening and local wound care 
or wound complication requiring surgery.” The stipulation that the complication would require 
subsequent surgical intervention represents an objective measure that somewhat offsets the 
broader and vaguer WHC criteria here. Golshan et al. defined a WHC to include seroma, 
abscess, hematoma, native or reconstruction flap necrosis, and cellulitis requiring antibiotic 
therapy. Including flap necrosis here is justified as many breast cancer patients undergo 
reconstruction following mastectomy. However, these umbrella criteria are broader than what is 
typically considered a wound-healing issue, such as abscess or cellulitis which may be 
unrelated.  
The remaining study, Jonasch et al., had a high potential for measurement bias as 
WHCs were defined as either wound dehiscence or “delayed wound healing”; the latter 
requirement is vague, qualitative, and easily variable depending on clinical judgment. 
Three of the studies (Gruenberger et al., Scappaticci et al., Allegra et al.) included a 
grading system with also ranked the severity of the reported WHC. Another two (Kesmodel et 
al., Golshan et al.) included stipulations in their WHC criteria such that only severe 
complications would be reported: Kesmodel et al. required surgical re-intervention, and Golshan 
et al. included only more serious complications. The remaining three (Jonasch et al., Clark et 
al., Kozloff et al.) did not include any schema which would separate severe WHCs from less-
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severe ones. In the lattermost group, the lack of differentiation by WHC-severity introduces bias 
as less-severe WHCs (such as healing delayed by one week) are weighted as equally as more-
severe WHCs (such as meningitis or osteomyelitis).  
 
Confounding Potential 
Many patient and procedural factors could independently and differentially affect the 
postoperative wound-healing status in these studies, other than the presence of bevacizumab 
therapy. Known confounders can be classified into patient variables, tumor variables, and 
procedural variables (Table 4). Potential patient confounders include age, gender, diabetes, 
hypertension, nutritional status, cardiovascular disease, peripheral arterial disease, liver 
disease, acute or chronic renal disease, and prior radiation therapy. Potential tumor 
confounders include type, stage, size and location of primary, and ease of resectability. 
Potential procedural confounders include type, duration of surgery, estimated-blood loss, 
location and size of incision, nature of concurrent chemotherapy, and duration between 
bevacizumab cessation and surgical intervention. 
 
Table 4. Potential Wound-Healing Confounders 
Patient Tumor Procedure 
Age 
Gender 
Diabetes 
Nutritional Status 
Cardiovascular Disease 
Peripheral Arterial Disease 
Liver Dysfunction 
Renal Disease 
Prior Radiation Therapy 
Type 
Stage 
Size 
Location of Primary 
Ease of Resectability 
Type 
Duration 
Incision Location and Size 
Estimated Blood Loss 
Concurrent Chemotherapy 
Bevacizumab-Surgery Duration 
 
 The ability of each study to address potential confounders primarily determined the 
certainty of its results. Four of the eight studies were considered to have minimal potential for 
confounding. Kesmodel et al.’s retrospective analysis compared cases of neoadjuvant 
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bevacizumab with chemotherapy against controls of neoadjuvant chemotherapy only before 
hepatic metastectomy. The two groups did not differ by age, stage, numerous comorbidities 
(cardiovascular disease, hypertension, pulmonary disease, renal disease, hepatobiliary disease, 
diabetes, BMI), and numerous procedural variables (procedure type, number and nature of 
neoadjuvant chemotherapy regimens, bevacizumab-surgery duration), although the 
bevacizumab cases did have a higher number of metastatic liver lesions (p = 0.04). Since the 
two groups did not differ significantly by numerous confounders that were properly reported, the 
final results are more trustworthy. Kozloff et al.’s cohort study also reported numerous potential 
confounders: age, race, gender, primary tumor site, mean preoperative albumin, proportion and 
type of prior adjuvant therapy, site of metastatic disease, diabetes, hypertension, arterial 
disease, anticoagulation therapy use, and bevacizumab-surgery duration. Many of these were 
controlled for via multivariate Poisson regression analysis, and thus adequate reporting with 
statistical normalization minimizes confounding here too. The other two studies (Allegra et al. 
and Scappaticci et al.) were randomized and high-powered, such that even though not all 
known specific confounders were reported, confounding was minimized if not eliminated. 
The remaining four studies were all rated as having high potential for confounding. 
Gruenberger et al. reported only basic patient information (age, gender, primary tumor site, 
hepatic metastases distribution) and ignored other potential confounders including patient 
comorbidity and procedural variables Similarly, Golshan et al. reported only basic patient 
information, ignored most tumor and procedure confounders, and did not compare the two 
groups in a formal, statistical manner. In addition, Clark et al.’s also did not report most patient, 
tumor, and procedural confounders, and neither did Jonasch et al. In all four studies, the final 
bevacizumab-related WHC incidence is very uncertain, as it remains difficult to attribute the 
recorded WHC incidence to bevacizumab therapy as opposed to the numerous potential 
patient, tumor, and/or procedural confounders. 
 
 
 
22 
 
Overall Study Quality 
 Overall study quality broke down as follows. Two studies were ultimately categorized as 
“Good” quality: Scappaticci et al.’s case-control analysis of neoadjuvant bevacizumab before 
hepatic resection of metastatic colorectal cancer and Allegra et al.’s randomized-controlled trial 
of adjuvant bevacizumab after primary resection of stage II and III colorectal cancer. Four 
studies were ultimately categorized as “Fair” quality: Gruenberger et al.’s case series of 
neoadjuvant and adjuvant bevacizumab before and after hepatic resection of metastatic 
colorectal cancer, Kesmodel et al.’s case-control analysis of neoadjuvant bevacizumab before 
hepatic resection of metastatic colorectal cancer, Kozloff et al.’s cohort study of neoadjuvant 
bevacizumab before hepatic resection of metastatic colorectal cancer, and Jonasch et al.’s 
cohort study of neoadjuvant bevacizumab before cytoreductive nephrectomy for renal cell 
carcinoma. Finally, the remaining two studies were classified as “Poor” quality”: Clark et al.’s 
case series of neoadjuvant and adjuvant bevacizumab before and after repeat craniotomy for 
recurrent glioblastoma multiforme, and Golshan et al.’s case series of neoadjuvant and adjuvant 
bevacizumab before and after surgical resection for triple-negative breast cancer. 
 
The Effect of Bevacizumab Therapy on Wound-Healing 
 The results of the “Good” studies can be concluded with the most certainty. Scappaticci 
et al. observed a 1.3% (95% CI: 0.3-3.8%) WHC rate in the adjuvant setting and a 13% (95% 
CI: 7-23%) in the neoadjuvant setting. Allegra et al. observed a 1.7% WHC rate with adjuvant 
bevacizumab, as opposed to 0.3% with adjuvant chemotherapy alone (p = 0.01). Importantly, 
both studies applied the same CTCAEv3.0 criteria to define wound-healing complications. Both 
yielded a WHC rate in the adjuvant bevacizumab setting that was similar and low, at ~2%. In 
addition, Scappaticci et al. supports the notion that neoadjuvant bevacizumab raises the WHC 
risk more than adjuvant bevacizumab (13% versus 1.3%), while Allegra et al. suggests that 
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adjuvant bevacizumab raises the WHC risk more than adjuvant chemotherapy alone (1.7% 
versus 0.3%). 
 The results from the “Fair” studies should be interpreted with more caution, though not 
discounted altogether. Gruenberger et al. found a 0% WHC rate amongst 56 mCRC patients, 
though only severe grade 3 and 4 complications were recorded, so less-severe WHCs may 
have occurred but not been considered. Kesmodel et al. reported a 28% WHC rate following 
neoadjuvant bevacizumab that did not differ significantly (p = 0.68) from the 25% WHC rate 
following neoadjuvant chemotherapy alone. This finding disagrees with Allegra et al. which 
implied a higher WHC risk than chemotherapy alone, though Kesmodel et al. occurred in the 
neoadjuvant setting and Allegra et al. in the adjuvant. Kozloff et al. reported a 4.4% (95% CI: 
2.7-6.2%) WHC rate after neoadjuvant bevacizumab. This is significantly smaller than 
Scappaticci et al.’s 13% rate, though the difference here can be attributed (at least partially) to 
differing WHC criteria. Jonasch et al. observed a 24% WHC rate after neoadjuvant 
bevacizumab, significantly higher than both Scappaticci et al.’s 13% and Kozloff et al.’s 4.4% 
rates, although these differences can be explained in part by both differences in WHC definition 
and tumor type (RCC vs. mCRC) and procedure (cytoreductive nephrectomy vs. hepatic 
metastectomy).  
 The results from the two “Poor” studies are highly uncertain and should be interpreted 
with utmost caution if used at all. Clark et al. observed an overall WHC incidence that was 
higher in the neoadjuvant setting (34.8%) than the adjuvant (5.6%), in agreement with 
Scappaticci et al. Golshan et al. reported a 43% WHC incidence after neoadjuvant bevacizumab 
that was not significantly different (p = 0.82) than the 39% rate after neoadjuvant cisplatin alone. 
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Discussion 
VEGF-targeted therapies, including the anti-VEGF antibody bevacizumab, are 
increasingly being investigated and utilized in the treatment of various advanced-stage 
malignancies, reflecting the growing understanding of VEGF-mediated angiogenesis in tumor 
survival and growth. However, as VEGF also mediates many normal physiological processes, 
including the vasodilation, increased vascular permeability, and angiogenesis necessary for 
proper wound healing, such bevacizumab use can be expected to lead to impaired wound 
healing and other wound-healing complications. The WHC risk confers special clinical 
significance as bevacizumab is employed in both neoadjuvant and adjuvant settings before 
and/or after surgical resection, and its anti-VEGF activity may impair wound healing of both 
primary and surrounding surgical incisions. This delay in wound healing may impair patient 
quality of life and in turn lead to serious sequelae including infection, hemorrhage, fasciitis, 
osteomyelitis, gross necrosis, and flap and/or reconstruction loss. In addition, it necessarily 
delays clinical benefit from resumption of bevacizumab therapy. Therefore, this systematic 
review is an attempt to survey the current clinical evidence and assess the incidence, timing, 
and nature of bevacizumab-related wound-healing complications. Such considerations should 
guide clinical judgment of timing of bevacizumab therapy and management decisions for 
bevacizumab-related WHCs. 
Of the eight articles included in final analysis, two were judged to be “Good” quality and 
another three to be “Fair”. The emerging consensus from the “Good” articles (Scappaticci et al., 
Allegra et al.) stipulates that bevacizumab does appear to raise the WHC risk more than 
chemotherapy alone, and that neoadjuvant bevacizumab appears to raise the WHC risk more 
than adjuvant bevacizumab. However, two considerations should be taken into account about 
these conclusions.  
First, the magnitude of these increases is less certain. Both the “Good” articles 
(Scappaticci et al., Allegra et al.) reported similar WHC rates following adjuvant bevacizumab 
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use (1.3% vs. 1.7%), using the same WHC definition (CTCAEv3.0) in the same clinical setting 
(hepatic resection for metastatic colorectal cancer). Moreover, Allegra et al. observed a 1.7% 
WHC rate after adjuvant bevacizumab that was statistically-significantly different than the 0.3% 
rate after adjuvant chemotherapy alone; however, the absolute increase in risk here is small, 
such that the clinical significance of increased WHC risk may not be as prominent. In addition, 
Scappaticci et al. observed a significant increase in WHC risk from neoadjuvant over adjuvant 
bevacizumab use (13% vs. 1.3%). Clark et al. agreed with this conclusion, but with a far greater 
increase (35% vs. 6%). 
Second, the applicability of these conclusions to other oncological indications with other 
WHC definitions is far less certain. Both “Good” articles employed the CTCAEv3.0 WHC criteria 
in patients with colorectal cancer. These conclusions cannot necessarily be generalized to 
breast cancer, renal cell carcinoma, glioblastoma multiforme, or non-small cell lung cancer. In 
fact, the other included studies performed in these indications sometimes found differing and 
opposing results. For example, both Golshan et al. (breast cancer) and Kesmodel et al. (stage 
IV colorectal cancer) did not find a significant difference in WHC incidence between 
bevacizumab versus chemotherapy alone, in disagreement with Allegra et al. (stage II and III 
colorectal cancer). Also, Jonasch et al. (cytoreductive nephrectomy for RCC) observed a higher 
WHC incidence after neoadjuvant bevacizumab than Scappaticci et al. (hepatic metastectomy 
for mCRC). While these studies were judged to be less quality and their results should 
consequently be interpreted with more uncertainty, it is important not to over-generalize results 
from the “Good” studies.   
Some of the difference in observed WHC risk between studies is attributable to varying 
definitions of what constitutes a wound-healing complication. While the CTCAEv3.0 provides a 
systematic and consistent guideline that was independently derived and therefore reduces 
measurement bias, it is not necessarily the best applicable in all settings. WHC criteria should 
differ by indication according to clinical significance and potential sequelae. For example, since 
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the incision for hepatic resection occurs in the abdomen, it is justifiable to consider an incisional 
hernia as a WHC here, though certainly not for a craniotomy incision occurring in the scalp. 
Conversely, a poorly-healing craniotomy wound may produce osteomyelitis, CSF leakage, and 
meningoencephalitis, rendering it justifiable to include these as pertinent WHCs in this setting 
but not in others. Thus, the specific criteria for wound-healing complications cannot be 
standardized across oncological indications, as each indication results in a different procedure 
for surgical resection, with an incision that differs by location and size, and a different profile of 
potentially-harmful sequelae secondary to impaired wound-healing. As such, meta-analysis of 
WHC risk across indication remains not possible. 
WHC criteria should be defined for future research purposes. Ideally, these criteria 
should be standardized within each oncological indication, independently-constructed by groups 
or committees other than the researching investigator, explicitly defined before initiation of the 
study, applied consistently to cases and controls, and as objective as possible, to minimize 
measurement bias. Furthermore, there should be some grading of WHCs to also report the 
severe complications, as is currently done in the CTCAEv3.0. Wound-healing complications can 
range from the somewhat mild (such as delayed wound-healing) to the very severe (such as 
skull flap necrosis producing meningoencephalitis), and it would be very helpful for providers to 
know both the rate of overall WHC and the rate of severe WHC when considering the toxicity 
profile of bevacizumab therapy. 
Many variables can confound the relationship between treatment and wound-healing. 
This review tried to systematically organize them into three categories: patient variables, tumor 
variables, and procedural variables. Several of the included studies attempted to methodically 
report and control for these potential confounders, thus strengthening their final analysis, while 
other studies simply ignored them, making their reported WHC risk far less attributable to the 
presence of bevacizumab. Future research should consider these potential confounders when 
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trying to assess the bevacizumab-related WHC risk, especially in the setting of oncological 
patients, many of whom suffer from high and complex comorbidity. 
General recommendations have already been provided regarding timing of bevacizumab 
therapy and onset of surgical intervention: bevacizumab therapy should occur at least 60 days 
before or 28 days after surgery[7, 33], should not be initiated until all surgical wounds are fully 
healed[7], and should be permanently discontinued if wound dehiscence occurs.[20] 
Bevacizumab treatment should also be withheld prior to elective surgery, though the interval 
here has not yet been optimized, with some recommending 4 weeks[7] and others 6-8 
weeks.[38] These recommendations rely chiefly on preclinical pathophysiological evidence, as 
bevacizumab’s long circulating half-life of ~20 days[5] necessitates an appropriate interval 
between treatment cessation and surgery to adequately prevent toxicities resulting from 
inhibition of VEGF-mediated physiological processes, including wound-healing complications. 
Thus, surgical oncologists apply conservative estimates of the bevacizumab-surgery 
interval, though these recommendations are not based on current clinical evidence. Importantly, 
it should be noted that any clinical benefit obtained by extending this interval and delaying 
bevacizumab therapy to minimize toxicity is necessarily offset by loss of bevacizumab’s 
therapeutic anti-tumor potential. Therefore, optimizing the duration of the bevacizumab-surgery 
interval remains an important goal for current and future research. None of the included studies 
specifically examined how the duration of this interval correlated with WHC risk.  
The current clinical evidence is unfortunately not of high enough quality to change or 
refine these management guidelines. Future research is required to assess the WHC risk of 
neoadjuvant and adjuvant bevacizumab therapy and to compare these risks to that of 
chemotherapy alone within each oncological indication. Future research is also required to 
evaluate how the duration of the bevacizumab-surgery interval correlates with increased WHC 
risk, if at all. Ideally, such studies would consist of prospective and high-powered trials within 
each of bevacizumab’s five oncological indications that compares the WHC incidence between 
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cases (patients who received bevacizumab) and controls (patients who didn’t). Furthermore, 
such studies should control for confounding (Table 4), either by multivariate analysis or ideally 
through randomization. In addition, such studies should employ clearly-defined, independently-
constructed WHC criteria that include some grading scheme to specify severe WHCs as well.  
Until then, the decision to proceed with surgical wound repair a certain time after bevacizumab 
cessation should depend on the clinical judgment and expertise of the managing multi-
disciplinary team (including both plastic surgeons and oncologists) that weighs the potential 
costs of preventable bevacizumab-associated toxicities against the potential anti-tumor benefits 
of bevacizumab use, along with knowledge of the patient’s underlying characteristics and 
expressed wishes, and not on a prefixed length that does not consider contextual specifics. 
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